Control Bionics (ASX:CBL) has reached a pivotal turning point in its European expansion strategy, announcing that its flagship NeuroNode device has secured a statutory reimbursement listing in Germany.
Following its formal inclusion in the Hilfsmittelverzeichnis under §139 SGB V (Position Number 16.99.04.1013), the wearable neural interface is now eligible for funding across Germany’s statutory health insurance funds.
The regulatory breakthrough effectively dismantles a major commercial barrier, validating the device’s safety and quality standards while facilitating immediate access for thousands of patients with motor impairments.
The listing serves as the catalyst for the company's strategic pivot toward a NeuroNode-only wholesale distribution model across the continent.
By shifting away from direct sales, Control Bionics aims to streamline market penetration and scale operations through local partnerships.
Management confirmed that the next phase involves appointing a German distributor and initiating pricing negotiations to commence pilot installations.
The European momentum follows a record FY25 revenue of $6.1 million, largely driven by US market penetration.
However, the expansion comes amidst a backdrop of financial tightening; the company reported a net loss of $6.1 million in FY25, relying on a $5.2 million capital raise and high-interest debt financing to sustain operations.
At the time of reporting, Control Bionics' share price was $0.059.